The Beginning of the End of Atherosclerosis?

Key Takeaways

• VERVE‑102 gene edit cuts LDL‑C up to 62% in Phase I trial.
• Single infusion aims for lifelong PCSK9 suppression, eliminating dosing adherence issues.
• Early safety signals include one Grade 3 pneumonitis; long‑term risks unknown.
• Gene therapy likely first approved for familial hypercholesterolemia or early ASCVD.
• PCSK9 inhibitors already cut cardiovascular events 15% over two years.

Pulse Analysis

The discovery of PCSK9’s role in LDL‑receptor regulation sparked a wave of therapeutics that have reshaped cardiovascular risk management. Monoclonal antibodies such as evolocumab and alirocumab, followed by siRNA‑based inclisiran, demonstrated that targeting PCSK9 can slash LDL‑C by roughly 60% and reduce major adverse cardiac events. These agents, however, depend on strict dosing schedules—bi‑monthly injections for antibodies and twice‑annual dosing for inclisiran—creating adherence challenges that blunt their real‑world effectiveness. The field has now turned to gene editing, aiming to replicate the lifelong benefit observed in rare loss‑of‑function PCSK9 mutations.

VERVE‑102, Eli Lilly’s base‑editing therapy, delivers a guide RNA and adenine base editor via lipid nanoparticles directly to the liver. By converting a single nucleotide in the PCSK9 gene, the therapy permanently halts PCSK9 production, mirroring the genetic knockout seen in protective human variants. In the Phase I trial, participants already on maximally tolerated statins experienced LDL‑C reductions ranging from 9% to a striking 62%, with the highest dose delivering a 78 mg/dL absolute drop. The durability of effect through at least one year suggests a true “once‑and‑done” solution, potentially eradicating the adherence gaps that cause 30‑50% of patients to discontinue lipid‑lowering drugs within a year.

If subsequent Phase II/III trials confirm safety and efficacy, VERVE‑102 could become the premium option for patients with familial hypercholesterolemia or early, aggressive atherosclerotic disease who cannot achieve target LDL‑C with existing therapies. Payers will likely restrict coverage to these high‑risk groups initially, given the anticipated high price tag of gene‑editing platforms. Nonetheless, the prospect of a permanent, low‑LDL state may shift the therapeutic paradigm, prompting insurers and clinicians to reevaluate cost‑effectiveness models that have traditionally favored chronic drug regimens. As the technology matures, broader indications could emerge, but long‑term surveillance will be essential to monitor off‑target effects and unforeseen safety issues.